GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference

Trending Topics in Gastroenterology

Explore current gastroenterology questions, clinical answers, and emerging research by topic.

11

Ozanimod Shows Real-World Effectiveness in UC, but Week-48 Results Need Cautious Interpretation: Medicina | September 2026

Introduction Ozanimod is an oral sphingosine-1-phosphate (S1P) receptor modulator approved for moderate-to-severe ulcerative colitis (UC), with efficacy established in the phase 3 True North program. However, real-world evidence...

12

REFINED-ASUC Rethinking How We Diagnose Acute Severe UC: CGH | August 2026

Introduction: Acute severe ulcerative colitis (ASUC) is still commonly diagnosed using the 1955 Truelove and Witts criteria. However, these criteria were developed long before corticosteroids, biologics, and small-molecule...

13

Does Removing More Mesentery Reduce Crohn’s Recurrence After Ileocolic Resection (MESOCOLIC Trial): Gastroenterology | September 2026

Introduction: Surgery is frequently required during the course of Crohn’s disease (CD), but the optimal extent of mesenteric resection remains controversial. Traditionally, Crohn’s surgery has emphasised bowel preservation...

14

Metabolic Syndrome Is Becoming a Major Modifier of IBD Outcomes: UEG Journal | August 2026

Introduction: IBD is increasingly recognised as a systemic inflammatory disease, while obesity and metabolic syndrome are becoming progressively more common in the same population. This large real-world study...

15

Risankizumab Performs Well in Real-World Crohn’s Disease—even After Ustekinumab (ARISE-CD): BMJ Open | August 2026

Introduction: Risankizumab, an IL-23 p19 inhibitor, is established for moderately to severely active Crohn’s disease based on phase III trials. ARISE-CD examined how well it performs in routine...

16

Duvakitug - Anti-TL1A Therapy in IBD: The Lancet Gastroenterology & Hepatology | August 2026

Introduction: Despite an expanding range of advanced therapies for inflammatory bowel disease (IBD), many patients fail to achieve durable remission or lose response over time. TL1A is an...

17

IBD in East and Southeast Asia: The Lancet Gastroenterology & Hepatology | August 2026

Introduction: Inflammatory bowel disease (IBD), historically concentrated in Western countries, is rapidly becoming a major healthcare challenge across East and Southeast Asia. This review examines a century of...

18

IUS Steroid Failure and Colectomy Risk in Pediatric ASUC: Gastroenterology | August 2026

Acute severe ulcerative colitis (ASUC) in children requires rapid identification of intravenous corticosteroid failure to avoid delayed rescue therapy and colectomy. Intestinal ultrasound (IUS) offers a noninvasive, repeatable...

19

IUS For Detecting Postoperative Crohn's Disease Recurrence: The Lancet Gastroenterology & Hepatology | July 2026

Introduction: Endoscopic assessment remains the standard for detecting postoperative recurrence after ileocolic resection in Crohn's disease, but it is invasive and resource-intensive. This international multidisciplinary RAND/UCLA consensus developed...

20

Diet and IBD Flares: Gut | July 2026

Introduction: Patients with inflammatory bowel disease (IBD) frequently ask whether diet influences disease relapse, yet high-quality prospective evidence has been scarce. The multicenter PREdiCCt study evaluated the impact...

Previous
12313
Next
GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer